The revolution of immuno-oncology therapy: specificities for the physicians

被引：0

作者：

Dubois, Manon ^{[1
]}

Ardin, Camille ^{[2
]}

Andre, Fanny ^{[1
]}

Scherpereel, Arnaud ^{[2
,3
,4
]}

Mortier, Laurent ^{[1
,3
,4
]}

机构：

[1] CHU Lille, Serv Dermatol, Lille, France

[2] CHU Lille, Serv Pneumol & Oncol Thorac, Lille, France

[3] Univ Lille, Lille, France

[4] Unite Inserm 1189 OncoThAI, Lille, France

来源：

M S-MEDECINE SCIENCES | 2020年 / 35卷 / 12期

关键词：

PEMBROLIZUMAB; IPILIMUMAB; PHASE-3;

D O I：

10.1051/medsci/2019226

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The use of immune checkpoint inhibitors has revolutionized the treatment and prognosis of many cancer patients. Associated with the raise of these new treatments, new side effects have been observed, requiring specific management. In addition, the tumor evolution and its monitoring under immunotherapy differ from conventional treatments, and require an adaptation of the radiological criteria for tumor lesions monitoring. Many other therapeutic targets exist and could potentially be associated with immune checkpoint inhibitors. Many challenges still need to be overcome in order to better understand and optimize the use of these new molecules.

引用

页码：946 / 948

页数：3

共 17 条

[1] Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma [J].

Adam, Julien ;

Tomasic, Gorana ;

Robert, Caroline .

ANNALES DE PATHOLOGIE, 2017, 37 (01) :55-60

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [J].

Boutros, Celine ;

Tarhini, Ahmad ;

Routier, Emilie ;

Lambotte, Olivier ;

Ladurie, Francois Leroy ;

Carbonnel, Franck ;

Izzeddine, Hassane ;

Marabelle, Aurelien ;

Champiat, Stephane ;

Berdelou, Armandine ;

Lanoy, Emilie ;

Texier, Matthieu ;

Libenciuc, Cristina ;

Eggermont, Alexander M. M. ;

Soria, Jean-Charles ;

Mateus, Christine ;

Robert, Caroline .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :473-486

[4] Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].

Champiat, Stephane ;

Ferrara, Roberto ;

Massard, Christophe ;

Besse, Benjamin ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762

[5]

Chouaid C, 2018, Rev Mal Respir, V10, P487, DOI 10.1016/s1877-1203(18)30004-1

[6] Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis [J].

Duruisseaux, Michael ;

Martinez-Cardus, Anna ;

Calleja-Cervantes, Maria E. ;

Moran, Sebastian ;

Castro de Moura, Manuel ;

Davalos, Veronica ;

Pineyro, David ;

Sanchez-Cespedes, Montse ;

Girard, Nicolas ;

Brevet, Marie ;

Giroux-Leprieur, Etienne ;

Dumenil, Coraline ;

Pradotto, Monica ;

Bironzo, Paolo ;

Capelletto, Enrica ;

Novello, Silvia ;

Cortot, Alexis ;

Copin, Marie-Christine ;

Karachaliou, Niki ;

Gonzalez-Cao, Maria ;

Peralta, Sergio ;

Montuenga, Luis M. ;

Gil-Bazo, Ignacio ;

Baraibar, Iosune ;

Lozano, Maria D. ;

Varela, Mar ;

Ruffinelli, Jose C. ;

Palmero, Ramon ;

Nadal, Ernest ;

Moran, Teresa ;

Perez, Lidia ;

Ramos, Immaculada ;

Xiao, Qingyang ;

Fernandez, Agustin F. ;

Fraga, Mario F. ;

Gut, Marta ;

Gut, Ivo ;

Teixido, Cristina ;

Vilarino, Noelia ;

Prat, Aleix ;

Reguart, Noemi ;

Benito, Amparo ;

Garrido, Pilar ;

Barragan, Isabel ;

Emile, Jean-Francois ;

Rosell, Rafael ;

Brambilla, Elisabeth ;

Esteller, Manel .

LANCET RESPIRATORY MEDICINE, 2018, 6 (10) :771-781

[7] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [J].

Eggermont, Alexander M. M. ;

Chiarion-Sileni, Vanna ;

Grob, Jean-Jacques ;

Dummer, Reinhard ;

Wolchok, Jedd D. ;

Schmidt, Henrik ;

Hamid, Omid ;

Robert, Caroline ;

Ascierto, Paolo A. ;

Richards, Jon M. ;

Lebbe, Celeste ;

Ferraresi, Virginia ;

Smylie, Michael ;

Weber, Jeffrey S. ;

Maio, Michele ;

Konto, Cyril ;

Hoos, Axel ;

de Pril, Veerle ;

Gurunath, Ravichandra Karra ;

de Schaetzen, Gaetan ;

Suciu, Stefan ;

Testori, Alessandro .

LANCET ONCOLOGY, 2015, 16 (05) :522-530

[8] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[9] Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab [J].

Hua, Camille ;

Boussemart, Lise ;

Mateus, Christine ;

Routier, Emilie ;

Boutros, Celine ;

Cazenave, Hugo ;

Viollet, Roxane ;

Thomas, Marina ;

Roy, Severine ;

Benannoune, Naima ;

Tomasic, Gorana ;

Soria, Jean-Charles ;

Champiat, Stephane ;

Texier, Matthieu ;

Lanoy, Emilie ;

Robert, Caroline .

JAMA DERMATOLOGY, 2016, 152 (01) :45-51

[10] Immune Checkpoint Inhibitor Toxicity in 2018 [J].

Johnson, Douglas B. ;

Chandra, Sunandana ;

Sosman, Jeffrey A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (16) :1702-1703

← 1 2 →